Gunji T, Tomita K, Koganezawa I, Nakagawa M, Yokozuka K, Ochiai S
BMC Gastroenterol. 2022; 22(1):519.
PMID: 36513977
PMC: 9749351.
DOI: 10.1186/s12876-022-02600-7.
Satake M, Yoshimatsu K, Sagawa M, Yokomizo H, Shiozawa S
Cancer Diagn Progn. 2022; 2(1):64-70.
PMID: 35400004
PMC: 8962845.
DOI: 10.21873/cdp.10077.
Chen L, Lin Y, Zhang Z, Yang R, Bai X, Liu Z
J Nanobiotechnology. 2021; 19(1):329.
PMID: 34666761
PMC: 8524854.
DOI: 10.1186/s12951-021-01064-3.
Sfeclan M, Mirea C, Ciorbagiu M, Vilcea A, Obleaga C, Padureanu V
Curr Health Sci J. 2019; 43(1):47-53.
PMID: 30595854
PMC: 6286729.
DOI: 10.12865/CHSJ.43.01.07.
Murcia O, Juarez M, Rodriguez-Soler M, Hernandez-Illan E, Giner-Calabuig M, Alustiza M
PLoS One. 2018; 13(9):e0203051.
PMID: 30188916
PMC: 6126803.
DOI: 10.1371/journal.pone.0203051.
Rectal Cancer Surveillance-Recurrence Patterns and Survival Outcomes from a Cohort Followed up Beyond 10 Years.
Tan W, Tan H, Dorajoo S, Foo F, Tang C, Chew M
J Gastrointest Cancer. 2017; 49(4):422-428.
PMID: 28660522
DOI: 10.1007/s12029-017-9984-z.
MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway.
Sheng N, Tan G, You W, Chen H, Gong J, Chen D
Cancer Med. 2017; 6(6):1331-1340.
PMID: 28440035
PMC: 5463071.
DOI: 10.1002/cam4.1029.
Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy.
Komori S, Osada S, Tomita H, Nishio K, Kumazawa I, Tachibana S
Mol Clin Oncol. 2014; 1(3):453-460.
PMID: 24649191
PMC: 3915693.
DOI: 10.3892/mco.2013.71.
Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence.
Hashimoto T, Itabashi M, Ogawa S, Hirosawa T, Bamba Y, Shimizu S
Surg Today. 2013; 44(5):902-5.
PMID: 24356986
PMC: 3986898.
DOI: 10.1007/s00595-013-0807-y.
Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution.
Yamaguchi K, Ogata Y, Akagi Y, Shirouzu K
Oncol Lett. 2013; 6(3):659-666.
PMID: 24137386
PMC: 3789105.
DOI: 10.3892/ol.2013.1433.
Prognostic impact of the metastatic lymph node ratio on survival in rectal cancer.
Attaallah W, Gunal O, Manukyan M, Ozden G, Yegen C
Ann Coloproctol. 2013; 29(3):100-5.
PMID: 23862127
PMC: 3710770.
DOI: 10.3393/ac.2013.29.3.100.
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Brady J, Corrie P, Chau I, Digumarti R, Adams L, Botbyl J
Invest New Drugs. 2013; 31(5):1228-35.
PMID: 23456563
DOI: 10.1007/s10637-013-9938-7.
Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K
BMC Cancer. 2012; 12:281.
PMID: 22769569
PMC: 3459783.
DOI: 10.1186/1471-2407-12-281.
Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.
Ogawa M, Watanabe M, Kobayashi T, Eto K, Oda A, Anan T
Int J Clin Oncol. 2012; 18(4):678-83.
PMID: 22585427
DOI: 10.1007/s10147-012-0424-6.
Clinical Significance of Lymph Node Ratio in Stage III Colorectal Cancer.
Park Y, Lee J, Park J, Jo H, Kang W, An C
J Korean Soc Coloproctol. 2011; 27(5):260-5.
PMID: 22102977
PMC: 3218131.
DOI: 10.3393/jksc.2011.27.5.260.
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y
Int J Clin Oncol. 2011; 17(1):1-29.
PMID: 22002491
DOI: 10.1007/s10147-011-0315-2.
Surveillance after curative resection of colorectal cancer.
Scheer A, Auer R
Clin Colon Rectal Surg. 2010; 22(4):242-50.
PMID: 21037815
PMC: 2796101.
DOI: 10.1055/s-0029-1242464.
The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery.
Galizia G, Orditura M, Ferraraccio F, Castellano P, Pinto M, Zamboli A
World J Surg. 2009; 33(12):2704-13.
PMID: 19760316
DOI: 10.1007/s00268-009-0207-z.
